Sökning: "pUUH239.2"

Hittade 3 avhandlingar innehållade ordet pUUH239.2.

  1. 1. Evolution and Mechanisms of Tigecycline Resistance in Escherichia coli

    Författare :Marius Linkevičius; Dan I. Andersson; Linus Sandegren; Patrice Courvalin; Uppsala universitet; []
    Nyckelord :Tigecycline; Bacterial resistance; Fitness; Escherichia coli; AcrAB; LPS; Tet proteins; Tet A ; Tet K ; Tet M ; Tet X ; tet genes; pUUH239.2; Mikrobiologi; Microbiology;

    Sammanfattning : Antibiotic resistance is an ongoing global medical crisis and we are in great need of new antibacterial agents to combat rapidly emerging resistant pathogens. Tigecycline is one of few drugs that have been introduced into medicine during the last two decades. LÄS MER

  3. 2. Mechanisms and Dynamics of Carbapenem Resistance in Escherichia coli

    Författare :Marlen Adler; Linus Sandegren; Josep Casadesús; Uppsala universitet; []
    Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; carbapenem; antibiotic resistance; fitness cost; ESBLs; penicillin-binding proteins; gene amplification;

    Sammanfattning : The emergence of extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae worldwide has led to an increased use of carbapenems and may drive the development of carbapenem resistance. Existing mechanisms are mainly due to acquired carbapenemases or the combination of ESBL-production and reduced outer membrane permeability. LÄS MER

  4. 3. Multi-Resistance Plasmids : Fitness Costs, Dynamics and Evolution

    Författare :Fredrika Rajer; Linus Sandegren; Pål Jarle Johnsen; Uppsala universitet; []
    Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; multi-resistance plasmids; evolution; fitness cost; dynamics; escherichia coli; ESBL; gene amplification; β-lactamase inhibitor; Biologi med inriktning mot mikrobiologi; Biology with specialization in Microbiology;

    Sammanfattning : Antibiotic resistance is an escalating problem, not only due to less desirable treatment options and outcome, but also due to the economic burden to health care caused by resistant pathogens. Since the process of developing new antibiotics is slow, we need to carefully consider the usage of the antibiotics still available. LÄS MER